Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469681 | 1.00 | AKT1 (0.41) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| Hydrochloric Acid SCHEMBL1469429 | 0.99 | AKT1 (0.41) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| Hydrochloric Acid SCHEMBL1469425 | 0.99 | AKT1 (0.41) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| SCHEMBL1468725 | 0.89 | LIMK2 (0.45) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| SCHEMBL1468728 | 0.89 | LIMK2 (0.45) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| SCHEMBL1469358 | 0.88 | MAPK1 (0.42) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| Alcohol SCHEMBL18037066 | 0.88 | AKT1 (0.40) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| SCHEMBL1469360 | 0.88 | MAPK1 (0.42) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| Hydrochloric Acid SCHEMBL1469176 | 0.88 | LIMK2 (0.44) | AKT1LIMK2ROCK2ROCK1CDC42BPB | |
| Hydrochloric Acid SCHEMBL1469172 | 0.88 | LIMK2 (0.44) | AKT1LIMK2ROCK2ROCK1CDC42BPB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969727-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9365568-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2990407-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2307409-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8758830-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8545897-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8178131-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | AKT1 669/4885LIMK2 760/4885ROCK2 1602/4885 |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | AKT1 669/4885LIMK2 760/4885ROCK2 1602/4885 |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | AKT1 537/4885LIMK2 711/4885ROCK2 1355/4885 |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | AKT1 669/4885LIMK2 760/4885ROCK2 1602/4885 |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | AKT1 669/4885LIMK2 760/4885ROCK2 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.